Re: Distribution Agreements

Deltex Medical Group PLC
3 December 2001



             Deltex Medical Group plc ('Deltex' / the 'Company')



DELTEX CONTINUES INTERNATIONAL SALES EXPANSION WITH NEW DISTRIBUTION
AGREEMENTS IN INDIA AND SOUTH AFRICA



Chichester, UK 3 December 2001 - Deltex (AIM: DEMG), the UK-based company
which develops, assembles and markets a non-invasive device for assessing
cardiac function, today announces that it has signed new distribution
agreements in India and South Africa for the CardioQ(TM) cardiac monitor and
probe, thereby continuing its strong international sales expansion drive.



India



India represents a large and growing healthcare market, with over one billion
inhabitants, representing the second largest population in the world.  In
1998, healthcare expenditure was over $22 billion* (6% of India's Gross
Domestic Production) and, in 2000, the Indian market for medical equipment and
supplies was valued at $990 million*.



Deltex has established an exclusive distribution partnership in India with the
Consolidated Products Corporation PVT LTD ('Consolidated Products') of New
Delhi, India.  Consolidated Products was established in 1972 and distributes a
range of products including cardiology, cardiovascular, critical care,
respiratory, and ophthalmic medical devices.



As a company focused on distributing leading-edge medical devices and
especially technologies which will improve the health and reduce the costs of
patient care, Consolidated Products is well positioned to introduce Deltex's
haemodynamic or blood flow technology.  It was the first company to introduce
the Swan Ganz, pulmonary artery catheter technology in India, providing a
strong understanding of the critical care area, the clinical importance of
blood flow and contacts with the key physician leaders in this important area
of medicine.



Consolidated Products distributes its products to all major regions in India,
covering both public and the fastest growing private hospital sectors.
Consolidated Products has around 65 employees and an annual turnover of over
$8 million.



South Africa



In 1999, South Africa had healthcare expenditures of over $10 billion*, which
represented 3.9% of their Gross Domestic Production and the value of the South
African market for medical equipment and supplies was $350 million*.



Trilogy Critical Care (Pty) Ltd and Aquila Business Systems (Pty) Ltd ('Trilogy 
and Aquila') of Randburg, South Africa are Deltex's distribution partners in 
South Africa.  Together acting as one company, they sell and service the Deltex 
products in South Africa.  The group consists of experts from the South African 
medical device industry.  Trilogy and Aquila represent a range of products in 
the anaesthesia, critical care, and cardiology medical device sectors and market
products in all major regions of South Africa.  They represent what they 
consider to be leading edge technologies and aim to capture at least 25% share 
of the market in key product ranges.  A special focus of Trilogy and Aquila is 
on the fast growing private hospital sector.



Commenting on these new distributor partnerships, Kemp Coady, Deltex's Chief
Executive Officer, said:



'India and South Africa are both fast growing health care markets where we
believe the Deltex products will aid greatly in the improvement of overall
patient care and in the reduction of health care costs.  These partnerships,
with the leading operators in their fields, represent an ideal way for Deltex
to enter these strategically important markets.



 'As demonstrated by our entry into India and South Africa, we continue to
strive to have our CardioQ technology accepted by medical practitioners
worldwide as the common method for guiding blood flow therapies on a real
time, beat to beat basis.'



Deltex's products are now being distributed in 15 countries worldwide.





*Data from Medistat, Episcom Business Intelligence, Lincoln House, City Fields
Business Park, Chichester, West Sussex


For further information, please contact:

Deltex Medical Group, plc                              [phone]
Kempton Coady, Chief Executive Officer
Ewan Phillips, Chief Financial Officer

Consolidated Products  Corporation, PVT. LTD           [phone]
Mr. Saigal, President

Trilogy Critical Care (Pty) Ltd                        [phone]
Mr. Wickham, President

Financial Dynamics
Sarah Mehanna/Andrew Dowler                            [phone]









Notes to Editors



Deltex develops, assembles and markets a non-invasive cardiac function monitor
and therapy guidance device, the CardioQ(TM) ('CardioQ(TM)'/'Monitor').  The
CardioQ(TM) incorporates the Company's proprietary software and a narrow,
easy-to-use, disposable oesophageal probe, used for transmitting and receiving
an ultra-sound ('Doppler') signal.  By using this Doppler technology, the
CardioQ(TM) provides clinicians with an early warning on the haemodynamic
condition of critically ill patients.  This continuous, real-time monitoring
facilitates the administration of fluids or drugs in a timely fashion and
provides an immediate assessment of their impact.



There are already over 600 CardioQ(TM)'s installed in hospitals worldwide -
approximately 380 in Europe, Australasian and Africa and 230 in the United
States.  In addition, there are currently more than 75 clinical publications
on the use of the CardioQ(TM) which have repeatedly:-



  * validated the results of the Monitor against known standards for
    measuring cardiac output, demonstrating that the technology works



  * proved that the CardioQ(TM) works over a variety of types of operation



  * shown that the Company's technology provides significant health and
    economic benefits by helping to reduce post-operative complications and
    length of hospital stays by an average of 30 to 40 per cent. for a wide
    range of patients.